Mass Gen­er­al team presents mouse da­ta to back the case for us­ing re­for­mu­lat­ed asth­ma drug to treat ALS

Can a re­for­mu­la­tion of an old drug on the mar­ket for asth­ma, al­ler­gy and mas­to­cy­to­sis pro­tect against liv­er dis­ease, Alzheimer’s, and amy­otroph­ic lat­er­al scle­ro­sis?

A team from Mass­a­chu­setts Gen­er­al Hos­pi­tal is mak­ing a case for the lat­ter two. Hav­ing re­cent­ly found an in­jec­tion of cro­molyn sodi­um ef­fec­tive in in­hibit­ing amy­loid be­ta (Aβ) ag­gre­ga­tion in vit­ro and in mouse mod­els, re­searchers set out to in­ves­ti­gate whether the same com­pound can achieve the same in ALS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER